Weight Watchers is Novo Nordisk's latest partnersip.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

A Wellington man is stoked to finally get his hands back on the weight loss drug he said changed his life. Wegovy was ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Weight-loss drugs like Ozempic, while revolutionary, are under scrutiny as the UK's MHRA investigates serious pancreas ...